PETA Science Group Shares Goals With New FDA Commissioner
PETA Science Consortium International e.V. and PETA scientist Jeffrey Brown share goals with new FDA Commissioner Dr. Robert Califf.
PETA scientist Jeffrey Brown of PETA Science Consortium International e.V. released a statement on Feb. 17, 2022 regarding new FDA Commissioner Dr. Robert Califf. The Science Consortium asked Califf in a letter to aid in steering the agency toward the use of animal-free science in place of requiring animal testing for new medical treatments. Califf expressed support for a shift toward the use of animal-free testing during his confirmation hearings.
“During your confirmation hearings, we appreciated your support for shifting toward the use of non-animal methods to enable more efficient pre-clinical development and evaluation of new drugs and devices,” Brown stated in the letter to Califf. “A reaffirmed commitment to demonstrate the FDA’s support of modern approaches to safety and efficacy assessment without the use of animals will generate a more human-relevant understanding of toxicity and efficacy while expediting the availability of treatments to patients.”
The organization highlighted its hope that Califf will support the FDA Modernization Act, which would change the FDA’s rules that require deadly tests on animals, including mice, dogs, and monkeys. The organization also believes Califf’s previous experience as FDA commissioner will benefit the advancement of animal-free science and testing.
Source: PETA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
